Neurology
Alzheimer’s Treatment Moves Home. Risk Does Not.
FDA approval of Leqembi Iqlik as a subcutaneous initiation dose could reduce infusion burden in early Alzheimer’s disease. But moving treatment closer to home does not make anti-amyloid care simple.
Parkinson’s Research Takes Aim at Mitochondrial Failure
Multiple System Atrophy Gets a Clearer FDA Pathway
The WHO’s first stroke resolution turns a clinical problem into a political one
Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority
Alzheimer’s Blood Testing Moves the Disease Clock Earlier
Huntington’s Disease Gets an Oral Target-Engagement Signal
A Urine Test for Alzheimer’s Would Change the Access Conversation
AlphaGenome Makes Variant Interpretation Political
AI Diagnosis Has Entered the Access Debate
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.